What We Stand For
In 2011, PhRMA member companies invested $50 billion in developing innovative new medicines to treat and cure diseases ranging from cancer and diabetes to Alzheimer's and Parkinson's. While we've come a long way, much remains to be done and the more than 600,000 sector employees are committed to achieving critical breakthroughs that keep patients healthy, reduce health care costs and improve millions of lives. Every day, we strive to do the following:
- Be a strong partner in an increasingly complex health care system;
- Drive America’s global leadership and innovation in biopharmaceutical research;
- Support vibrant communities across the country through our investment, research, clinical trials and other work;
- And, deliver progress for patients who depend on this industry to discover new medicines that help us live longer, more productive lives.
From Hope to Cures. Join us today.
Advancing Research
The next major medical discovery is within our collective reach. That’s because helping patients live healthy and productive lives is at the core of everything we do. Our member companies have invested $50 billion in 2011 to develop new medicines and our work is only getting started. Combine this with our commitment to promoting jobs and strengthening the U.S. economy – that’s who we are.
- Medicines in Development - With roughly 2,900 medicines currently in development, the promise for remarkable advances in treatment for all diseases is stronger than ever.
- Drug Discovery And Development - On average, it takes 15 years from discovery to approval for a new medicine to join the market.
- Give Kids An Inch, They’ll Give You A Breakthrough - Collaboration among members of the research ecosystem allows biopharmaceutical researchers to break ground.
- Biopharmaceutical Industry Vendor and Supplier Maps - These three maps highlight the biopharmaceutical industry’s partnerships with both large and small businesses.
- Partnerships and Industry Dedication Continue in the Global Fight Against AIDS - See what PhRMA member companies are doing to tackle the three largest global AIDS challenges.